The Food and Drug Administration today released a final rule regulating certain protein products, such as insulin, as biological products rather than drugs effective March 23. Authorized by the Biologics Price Competition and Innovation Act of 2009, the change will allow new insulin products, and certain other protein products, to apply for marketing approval through the abbreviated pathway for biosimilar or interchangeable products in an effort to increase market competition and lower prices. For more on the change, see the FDA FAQs for health care providers and patients

In other news, FDA today released a table of gene-drug interactions based on FDA labeling and other scientific evidence, which it plans to update periodically to aid prescribers. 
 

Related News Articles

Headline
President Trump today released his discretionary spending budget blueprint for fiscal year 2026. The “skinny budget” request, which includes top line…
Headline
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State…
Perspective
Public
Congressional lawmakers are heading home for a two-week district work period after both the Senate and House passed a revised budget resolution for fiscal year…
Headline
The House, by a vote of 216-214, passed the revised budget resolution for fiscal year 2025. This follows the Senate’s passage of the bill last week. Reps…
Headline
House Republican leaders March 8 unveiled a bill that would fund the federal government through Sept. 30 of this year, as well as extend certain key health…
Perspective
All of America’s hospitals and health systems are cornerstones of their communities. They not only deliver around-the-clock care and essential services to…